BR112016030424A2 - construções de anticorpo multiespecíficas - Google Patents

construções de anticorpo multiespecíficas

Info

Publication number
BR112016030424A2
BR112016030424A2 BR112016030424A BR112016030424A BR112016030424A2 BR 112016030424 A2 BR112016030424 A2 BR 112016030424A2 BR 112016030424 A BR112016030424 A BR 112016030424A BR 112016030424 A BR112016030424 A BR 112016030424A BR 112016030424 A2 BR112016030424 A2 BR 112016030424A2
Authority
BR
Brazil
Prior art keywords
multispecific antibody
antibody constructs
vectors
formula
present disclosure
Prior art date
Application number
BR112016030424A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Humphreys David
Dave Emma
Bhatta Pallavi
Philip Heywood Sam
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112016030424A2 publication Critical patent/BR112016030424A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112016030424A 2014-06-26 2015-06-25 construções de anticorpo multiespecíficas BR112016030424A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411420.1A GB201411420D0 (en) 2014-06-26 2014-06-26 Antibody constructs
PCT/EP2015/064450 WO2015197789A1 (en) 2014-06-26 2015-06-25 Multi-specific antibody constructs

Publications (1)

Publication Number Publication Date
BR112016030424A2 true BR112016030424A2 (pt) 2017-10-24

Family

ID=51410201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030424A BR112016030424A2 (pt) 2014-06-26 2015-06-25 construções de anticorpo multiespecíficas

Country Status (10)

Country Link
US (1) US20170198062A1 (enExample)
EP (1) EP3161008B1 (enExample)
JP (1) JP2017528117A (enExample)
CN (1) CN106459217A (enExample)
BR (1) BR112016030424A2 (enExample)
CA (1) CA2953638A1 (enExample)
ES (1) ES2763525T3 (enExample)
GB (1) GB201411420D0 (enExample)
RU (1) RU2710730C2 (enExample)
WO (1) WO2015197789A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2758432T (pt) * 2011-09-16 2019-06-14 Ucb Biopharma Sprl Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
KR20240165484A (ko) 2017-04-11 2024-11-22 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
CN119143877A (zh) * 2020-03-03 2024-12-17 成都百利多特生物药业有限责任公司 抗cd19抗体及其使用和制备方法
BR112022019047A2 (pt) 2020-03-27 2022-11-01 UCB Biopharma SRL Peptídeos de domínio knob autônomos
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2246538C2 (ru) * 1998-05-20 2005-02-20 Чугаи Сейяку Кабусики Кайся Способ и набор для выявления гена, кодирующего мембраносвязанный белок, вектор (варианты)
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2700714C (en) * 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010027981A1 (en) * 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
MX2011003133A (es) * 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
ES2536996T3 (es) * 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Anticuerpos biespecíficos de unión a digoxigenina
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CA2867020C (en) * 2012-03-13 2022-11-15 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format

Also Published As

Publication number Publication date
RU2017102312A (ru) 2018-07-26
EP3161008B1 (en) 2019-09-25
CA2953638A1 (en) 2015-12-30
RU2017102312A3 (enExample) 2019-02-15
ES2763525T3 (es) 2020-05-29
CN106459217A (zh) 2017-02-22
WO2015197789A1 (en) 2015-12-30
US20170198062A1 (en) 2017-07-13
EP3161008A1 (en) 2017-05-03
RU2710730C2 (ru) 2020-01-10
GB201411420D0 (en) 2014-08-13
JP2017528117A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX372679B (es) Moleculas de union para bcma y cd3.
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX381278B (es) Composición para la estimulación ovárica controlada.
BR112017004495A2 (pt) variantes de celobiohidrolase e polinucleotídeos codificando as mesmas
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112017003263A2 (pt) anticorpos anti-vasa, e métodos de produção e utilização dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements